As of November 6, 2026, Arcutis Biotherapeutics, Inc. is a publicly traded company (Nasdaq: ARQT). The largest holder reporting an active stake on Schedule 13D is Frazier Life Sciences VIII, L.P., at 7.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (14.1%), Rubric Capital Management LP (6.75%), Polar Capital Holdings Plc (5.28%) (Schedule 13D/A, August 20, 2025).
Is this your company?
About to sign with, pay or invest in Arcutis Biotherapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Arcutis Biotherapeutics, Inc. a real, registered company?
- Arcutis Biotherapeutics, Inc. files with the SEC under CIK 1787306 (its SEC filings).
- Its shares are listed under the ticker ARQT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Westlake Village, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ARCUTIS BIOTHERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Robert Scott, Director (Form 8-K filed 2026-10-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-05).
Who are Arcutis Biotherapeutics, Inc.'s owners and officers?
Arcutis Biotherapeutics, Inc.: incorporated in Delaware; business address in Westlake Village, California; industry Pharmaceutical Preparations (Form D, 2026-10-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-05 | Blackrock, Inc. | 14.1% |
| Schedule 13G, 2026-08-14 | Polar Capital Holdings PLC | 5.28% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 4.7% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 5.1% |
| Schedule 13G/A, 2026-05-08 | Prudential Financial Inc | 4.3% |
| Schedule 13G/A, 2026-05-06 | Jennison Associates LLC | 4% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-13 | Rubric Capital Management LP | 6.75% |
| Schedule 13G/A, 2026-02-13 | Prudential Financial Inc | 5.7% |
| Schedule 13G/A, 2026-01-30 | Jennison Associates LLC | 5.5% |
| Schedule 13G/A, 2025-10-06 | Jennison Associates LLC | 10.2% |
| Schedule 13D/A, 2025-08-20 | Frazier Life Sciences Viii, L.P. | 7.5% |
Questions about who owns Arcutis Biotherapeutics, Inc.
Who owns Arcutis Biotherapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Arcutis Biotherapeutics, Inc.: Blackrock, Inc. (14.1%, Schedule 13G/A, filed 2026-10-05), Frazier Life Sciences Viii, L.P. (7.5%, Schedule 13D/A, filed 2025-08-20), Rubric Capital Management LP (6.75%, Schedule 13G/A, filed 2026-02-13) and Polar Capital Holdings PLC (5.28%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Arcutis Biotherapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Arcutis Biotherapeutics, Inc. on this page are Blackrock, Inc. (14.1%), Frazier Life Sciences Viii, L.P. (7.5%) and Rubric Capital Management LP (6.75%).
When did Blackrock, Inc. buy into Arcutis Biotherapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-10-05, reporting 14.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Arcutis Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arcutis Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcutis Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-28 | Robert Scott | Director | appointed | |
| Form 8-K, 2026-08-05 | L. Todd Edwards | departed | 2026-08-21 | |
| Form 8-K, 2026-08-05 | Robert Lisicki | appointed | ||
| Form 8-K, 2026-07-16 | Christopher Peetz | Director | appointed |
Which insiders own Arcutis Biotherapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 917,807 shares (0.73% of shares outstanding), 867,826 held directly and 49,981 indirectly (Form 4, 2025-06-16).
- , a director: 895,140 shares (0.71% of shares outstanding), 712,826 held directly and 182,314 indirectly (Form 4, 2026-11-04).
- , a director: 191,815 shares (0.15% of shares outstanding), 4,315 held directly and 187,500 indirectly (Form 4, 2026-07-17).
- , the chief financial officer: 182,774 shares (0.14% of shares outstanding) (Form 4, 2025-04-03).
- L. Todd Edwards: 175,178 shares (0.14% of shares outstanding) (Form 4, 2026-03-03).
Shares outstanding: 126,455,033 as of 2026-10-30, from the company's latest SEC cover page.
How much has Arcutis Biotherapeutics, Inc. raised?
No fundraising or offering filing from Arcutis Biotherapeutics, Inc. is on file with us.
Keep reading
More on Arcutis Biotherapeutics, Inc. and the records around it.
Arcutis Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Aug 2026
Companies that share a holder
- Polar Capital Holdings Plc also filed stake reports on 3 other companies: Verastem, Inc. (Jul 2026), ENLIVEN THERAPEUTICS, INC. (Jun 2026), HAGERTY, INC. (Sep 2025)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- PRUDENTIAL FINANCIAL INC also filed stake reports on 20 other companies: National Healthcare Properties, Inc. (Oct 2026), Neurogene Inc. (Oct 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/arcutis-biotherapeutics